SGLT2 Inhibitors and Mechanisms of Hypertension
- 19 January 2018
- journal article
- review article
- Published by Springer Nature in Current Cardiology Reports
- Vol. 20 (1) , 1
Abstract
We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension.Keywords
This publication has 54 references indexed in Scilit:
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic miceEuropean Journal of Pharmacology, 2013
- DapagliflozinDrugs, 2012
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetesBMJ Open, 2012
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 DiabetesDiabetes Care, 2012
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on MetforminThe Journal of Clinical Endocrinology & Metabolism, 2012
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic ratAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trialsAnnals of Medicine, 2011
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011
- Renal glucose reabsorption inhibitors to treat diabetesTrends in Pharmacological Sciences, 2011
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot studyCardiovascular Diabetology, 2010